Contents 3 min read

Claim and source comparison

Piracetam: cognition and stroke reviews, and product information on safety and pharmacokinetics.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Systematic review / meta-analysis

The 2002 meta-analysis pooled 19 placebo-controlled trials in older people with cognitive impairment or dementia. Global clinical change ratings favored piracetam.

This global rating is distinct from specific memory tests. The abstract does not establish benefit in healthy young people. The first author was affiliated with manufacturer UCB.

Source 6 · Abstract read

Systematic review / meta-analysis

The Ricci et al. (2012) Cochrane review included 3 trials and 1002 patients with acute ischemic stroke. Efficacy and safety remained inconclusive; consistent neurological recovery or established neuroprotection was not demonstrated.

One trial supplied 93% of the data. Evidence on dependence was insufficient, and adverse effects were not reported. The review does not establish safe use.

Source 4 · Abstract read

Official safety summary

Piracetam is renally eliminated; dose adjustment is needed with impaired renal function and severe renal failure is a contraindication. Cerebral hemorrhage and Huntington chorea are contraindications. Bleeding risk, anticoagulants/antiplatelets and planned surgery require medical review. Abrupt withdrawal in myoclonus can trigger seizures.

These warnings come from the UK Nootropil product information for adult cortical myoclonus. They do not establish other cognitive indications or approval status in other countries.

Source 7 · Official summary read

Human pharmacokinetic study

The Nootropil product information reports a plasma half-life of 5 hours in young adult men. Elimination depends on kidney function.

This duration does not establish a personal medication schedule or a constant for kidney impairment. It is not used for a general profile curve.

Source 7 · Official summary read

Cell / laboratory study

In the 1997 experiment, piracetam increased the fluidity of aged mouse, rat and human brain membranes in vitro.

An in vitro human-tissue measure is distinct from memory outcomes after treating patients. Learning findings in aged rats cannot be directly transferred to humans.

Source 5 · Abstract read

Our evidence and source methodology

Piracetam: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Piracetam?

Piracetam is a synthetic racetam used as a medicine for cortical myoclonus in certain countries. Evidence is not equivalent for dementia, stroke or cognitive enhancement in healthy people; prescribing conditions and renal function matter.

Mechanism of Effect

In the 1997 experiment, piracetam increased the fluidity of aged mouse, rat and human brain membranes in vitro.

An in vitro human-tissue measure is distinct from memory outcomes after treating patients. Learning findings in aged rats cannot be directly transferred to humans.

Clinical Evidence

Age-Related Cognitive Decline

The 2002 meta-analysis pooled 19 placebo-controlled trials in older people with cognitive impairment or dementia. Global clinical change ratings favored piracetam.

This global rating is distinct from specific memory tests. The abstract does not establish benefit in healthy young people. The first author was affiliated with manufacturer UCB.

Myoclonus Epilepsy

These warnings come from the UK Nootropil product information for adult cortical myoclonus. They do not establish other cognitive indications or approval status in other countries.

Dyslexia and Learning Disabilities

Wilsher and colleagues’ 1987 trial enrolled 225 children with dyslexia. Some reading measures improved in the 36-week placebo-controlled trial. Findings in this selected group do not establish general cognitive enhancement in healthy adults.

Recovery After Brain Injury

The Ricci et al. (2012) Cochrane review included 3 trials and 1002 patients with acute ischemic stroke. Efficacy and safety remained inconclusive; consistent neurological recovery or established neuroprotection was not demonstrated.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

The Nootropil product information reports a plasma half-life of 5 hours in young adult men. Elimination depends on kidney function.

This duration does not establish a personal medication schedule or a constant for kidney impairment. It is not used for a general profile curve.

Controlled human trials have not established that choline supplementation is mandatory with racetams or prevents headaches.

Safety and Side Effects

Piracetam is renally eliminated; dose adjustment is needed with impaired renal function and severe renal failure is a contraindication. Cerebral hemorrhage and Huntington chorea are contraindications. Bleeding risk, anticoagulants/antiplatelets and planned surgery require medical review. Abrupt withdrawal in myoclonus can trigger seizures.

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

Sources

  1. Giurgea C. (1972). [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology]. Actualités pharmacologiques, 25, 115–56. PubMed · PMID 4541214
  2. Winblad, B. (2005). Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Reviews, 11(2), 169–182. PubMed · PMID 16007238
  3. Wilsher, C.R. et al. (1987). Piracetam and dyslexia: effects on reading tests. Journal of Clinical Psychopharmacology, 7(4), 230–237. PubMed · PMID 3305591
  4. Ricci, S. et al. (2012). Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews, Issue 9. PubMed · PMID 22972044
  5. Müller, W.E. et al. (1997). Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochemical Pharmacology, 53(2), 135–140. PubMed · PMID 9037245
  6. Waegemans, T. et al. (2002). Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dementia and Geriatric Cognitive Disorders, 13(4), 217–224. PubMed · PMID 12006732
  7. ADVANZ Pharma. Nootropil 1200 mg film-coated tablets: Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/101131/smpc ADVANZ Pharma / electronic medicines compendium

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions